Company profile: Tryp Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage psilocybin-based therapeutics, developing an IV infusion of psilocin and synthetic oral psilocybin to address neuropsychiatric disorders, orphan diseases, and conditions with no effective first-line treatments. Offerings include TRP-8803, a proprietary IV psilocin formulation, TRP-8802 in early-stage trials, and Phase 2a studies in fibromyalgia, binge eating disorder, and irritable bowel syndrome.
Products and services
- TRP-8803: Proprietary psilocin delivered via intravenous infusion—the active metabolite of psilocybin—architected to address neuropsychiatric disorders by amplifying psilocybin’s effects while reducing its limitations
- Phase 2a Clinical Trials: Phase 2a evaluations measuring efficacy of Tryp’s psilocybin-based compounds for fibromyalgia, binge eating disorder, and irritable bowel syndrome
- TRP-8802: Synthetic psilocybin in oral form employed in early-stage clinical trials to demonstrate potential benefits for treating neuropsychiatric disorders
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tryp Therapeutics
Oscine Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology innovations based on discoveries made and developed at the University of Rochester Medical Center.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oscine Therapeutics company profile →
Sonoma Bio
HQ: United States
Website
- Description: Provider of Treg and Teff cell therapies and autoimmune disease research, developing adoptive Treg therapies for rheumatoid arthritis, inflammatory bowel disease, and hidradenitis suppurativa. Pipeline includes SBT-77-7101, a Treg cell therapy targeting citrullinated proteins to reduce inflammation, and SBT-11-5301, a Phase 1 effector T cell-modulating biologic, with clinical trials assessing safety and effectiveness.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sonoma Bio company profile →
Cingulate
HQ: United States
Website
- Description: Provider of precision timed-release therapeutics combining delivery technology with proven medications to deliver rapid-onset, once-daily, full-day efficacy. Portfolio includes ADHD treatments CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), and CTx-2103 (buspirone HCl) for anxiety under development, powered by its Precision Timed Release (PTR) platform enabling predefined release times.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cingulate company profile →
Chestnut Medical
HQ: United States
Website
- Description: Provider of minimally invasive therapies and technologies for interventional neuroradiology, focused on improving outcomes and reducing complications in the treatment of neurovascular disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chestnut Medical company profile →
Balt
HQ: France
Website
- Description: Provider of interventional neuroradiology (INR) devices for treating strokes, aneurysms, and arteriovenous malformations. BALT designs, manufactures, and distributes essential devices such as catheters, stents, and coils, working with neurovascular surgeons to address complex, life-threatening conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Balt company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tryp Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tryp Therapeutics
2.2 - Growth funds investing in similar companies to Tryp Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tryp Therapeutics
4.2 - Public trading comparable groups for Tryp Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →